Skip to main content

Advertisement

SpringerLink
Log in

Advantages of Multiplex Proteomics in Clinical Immunology

The Case of Rheumatoid Arthritis: Novel IgXplex™ Planar Microarray Diagnosis

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Clinical multiplex diagnostic proteomics is the application of proteomic technologies to improve a patient’s clinical outcomes. The future holds impact potential for testing prognosis, diagnosis, and drug therapy, while monitoring efficacious treatment with qualitative and quantitative data. Multiplex clinical diagnostic use of novel biomarkers in body fluids to confirm presence and severity of clinical disease states, holds great promise for clinical use. Challenges for diagnostic clinics include awareness of proteome complexity in clinical samples, the effects of high-abundance proteins, such as albumin, that could mask detection of other and low abundance disease proteins or biomarkers. Standardized approaches to sample collection and preparation, new analytical techniques and novel algorithms for bio-statistical analysis will facilitate release of the great potential of clinical multiplex diagnostic proteomics. A sensitive RA assay has been developed for the simultaneous measurement of the three rheumatoid factors (RFs), RF-IgA, IgG, and IgM, with the option to simultaneously measure anti-cyclic citrullinated peptide (anti-CCP) IgG antibodies using IgXplex™ technology. Testing 10-μL serum samples, SQI’s multiplex microarray rheumatoid arthritis assay provides both positive/negative as well as qualitative/semi-quantitative results for anti-CCP IgG, RF-IgA, IgG, and IgM in each sample well on a 96-well microtiter-formatted microarray plate. Signal detection uses sensitive fluorescent-tagged markers captured onto planar microarray spots and read in a microarray scanner. Each result is verified with confidence confirmation technology and validating quality controls in every sample well. For an 80-RA positive patient cohort, the 4-PLEX profile sensitivity was determined at 82.5%. The specificity for the 44 RA healthy control cohort was determined at 97.7%. The multiplex data also demonstrated that a patients’ severity of disease profile, mild to severe, correlates the status of RA biomarkers to disease status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wu T, Mohan C (2009) Proteomic toolbox for autoimmunity research. Autoimmunity Reviews 8:595–598

    Article  PubMed  CAS  Google Scholar 

  2. Hueber W, Robinson WH (2009) Genomics and proteomics: applications in autoimmune diseases. Pharmacogenomics Personalized Medicine 2:39–48

    Article  CAS  Google Scholar 

  3. (2008) In: Shoenfeld Y, Cervera R, Gershwin ME (eds) Diagnostic criteria in autoimmune diseases, doi:10.1007/978-160327-285-8_5, Humana, Totowa, NJ, U.S.A.

  4. Lea P, Ling M (2008) New molecular assays for cancer diagnosis and targeted therapy. Current Opinion Molecular Therapeutics 10:251–259

    CAS  Google Scholar 

  5. Cano L, Arkfeld DG (2009) Targeted synovial fluid proteomics for biomarker discovery in rheumatoid arthritis. Clinical Proteomics 5:75–102

    Article  CAS  Google Scholar 

  6. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983

    Article  PubMed  CAS  Google Scholar 

  7. Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, Klee GG, Kullo I, Laguna TA, Roth FP, Sabatine M, Srinivas P, Wang TJ, Ware LB (2008) Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol 295:L16–L22

    Article  PubMed  CAS  Google Scholar 

  8. Rhigetti PG, Castagna A, Antonucci F et al (2003) The proteome: anno Domini 2002. Clin Chem Lab Med 41:425–438

    Article  Google Scholar 

  9. Tilleman K, DeForce D, Elewaut D (2005) Rheumatology: a close encounter with proteomics. Rheumatology 44:1217–122

    Article  PubMed  CAS  Google Scholar 

  10. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A (2004) The human plasma proteome: a non-redundant list developed by combination of four separate sources. Mol Cell Proteomics 3:311–326

    Article  PubMed  CAS  Google Scholar 

  11. Bjorhall K, Miliotis T, Davidsson P (2005) Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 5:307–317

    Article  PubMed  Google Scholar 

  12. Anderson NL, Anderson NG, Haines LR, Hardi DB, Olafson RW, Pearson TW (2004) Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies. J Proteome Res 3:235–244

    Article  PubMed  CAS  Google Scholar 

  13. Elia G, Silacci M, Scheurer S, Scheuermann J, Neri D (2002) Affinity-capture reagents for protein arrays. Trends Biotechnol 20:S19–S22

    Article  PubMed  CAS  Google Scholar 

  14. Martosella J, Zolotarjova N, Liu H, Nicol G, Boyes BE (2005) Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J Proteome Res 4:1522–1537

    Article  PubMed  CAS  Google Scholar 

  15. Morozov VN, Morozova TY (2006) Active bead-linked immunoassay on protein microarrays. Anal Chim Acta 564:40–52

    Article  PubMed  CAS  Google Scholar 

  16. Sagel SD, Chmiel JF, Konstan MW (2007) Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 4:406–417

    Article  PubMed  CAS  Google Scholar 

  17. Whiteaker JR, Zhao L, Zhang HY, Feng LC, Piening BD, Anderson L, Paulovich AG (2007) Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem 362:44–54

    Article  PubMed  CAS  Google Scholar 

  18. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983

    Article  PubMed  CAS  Google Scholar 

  19. Glokler J, Angenendt P (2003) Protein and antibody microarray technology. J Chromatogr B Analyt Technol Biomed Life Sci 797:229–240

    Article  PubMed  CAS  Google Scholar 

  20. SQI Diagnostic Systems, www.sqidiagnostics.com

  21. Bio-Rad Laboratories. Bio-Rad Bio-Plex System and Suspension Array Technology, accessed December 2007

  22. Melton L (2004) Protein arrays: proteomics in multiplex. Nature 429:101–107

    Article  PubMed  Google Scholar 

  23. Kersten B, Wanker EE, Hoheisel JD, Angenendt P (2005) Multiplex approaches in protein microarray technology. Expert Rev Proteomics 2:499–510

    Article  PubMed  CAS  Google Scholar 

  24. Waterboer T, Sehr P, Pawlita M (2006) Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 309:200–204

    Article  PubMed  CAS  Google Scholar 

  25. US Department of Health and Human Services and Food and Drug Administration Center for Devices. Draft Guidance for Industry, Clinical Laboratories, and FDA Staff. In Vitro Diagnostic Multivariate Index Assays, accessed December 2007

  26. Mueller GA, Mueller CA, Dihazi H (2007) Clinical proteomics—on the long way from bench to bedside? Nephrol Dial Transplant, doi:10.1093/ndt/gfl806

  27. Rai AJ, Vitzthum F (2006) Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 3:409–426

    Article  PubMed  CAS  Google Scholar 

  28. Villanueva J, Philip J, Chaparro CA, Li Y, Toledo-Crow R, DeNoyer L, Fleisher M, Robbins RJ, Tempst P (2005) Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4:1060–1072

    Article  PubMed  CAS  Google Scholar 

  29. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358:903–911

    Article  PubMed  CAS  Google Scholar 

  30. Palosuo T, Tilvis R, Strandberg T, Aho K (2003) Fiaggrin related antibodies among the aged. Ann Rheum Dis 62:261–263

    Article  PubMed  CAS  Google Scholar 

  31. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J et al (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis. A multiparameter prospective study. Arthritis Rheum 44:1736–1743

    Article  PubMed  CAS  Google Scholar 

  32. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of radiographic outcome in rheumatoid arthritis. Ann Rheum Dis 64:196–201

    Article  PubMed  CAS  Google Scholar 

  33. Szodoray P, Szabo Z, Kapitany A, Gyetvai A, Lakos G, Szanto S, Szues G, Szekanecz Z (2009) Anti citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev [Epub ahead of print]: May 7, in press

  34. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arth Res 4:87–93

    Article  Google Scholar 

  35. Steiner G, Smolen JS (2002) Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 4:S1–S5

    Article  PubMed  Google Scholar 

  36. Marcelletti JF, Nakamura RM (2003) Assessment of serological markers associated with rheumatoid arthritis: diagnostic autoantibodies and conventional disease activity markers. Clin Appl Immunol Rev 4:109–123

    Article  CAS  Google Scholar 

  37. Zendman AJW, van Venrooij WJ, Pruijn GJM (2006) Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology 45:20–25

    Article  PubMed  CAS  Google Scholar 

  38. Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163

    Article  PubMed  CAS  Google Scholar 

  39. Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680

    Article  PubMed  CAS  Google Scholar 

  40. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R (2001) Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47(6):1089–1093

    PubMed  CAS  Google Scholar 

  41. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning HMT, Habibuw MR, Vandenbroucke JP, Dijkmans BAC (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386

    Article  PubMed  Google Scholar 

  42. Raza K, Breese M, Nightingale P et al (2005) Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 32:231–238

    PubMed  CAS  Google Scholar 

  43. O’Connor TET, Morris A, Smith K, Ricks C, Lea P (2009) Automated Quantitative multiplexed microarray platform. IVD Technology 15(9):43–49

    Google Scholar 

  44. Berglin E (2006) Predictors of disease onset and progression in early rheumatoid arthritis. A Clinical, Laboratory and Radiological Study. Umea University Medical Dissertations: ISBN 91-7264-003-0. Dept Public Health and Clinical Medicine, Rheumatology, Umea, Sweden

  45. Atzeni F, Sarzi-Puttini P, Dell’ Aqua D, de Portu S, Cecchini G, Cruini C, Carabba M, Meroni PL (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arth Res & Ther 8:R3

    Article  Google Scholar 

  46. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis & Rheumatism 46:357–365

    Article  Google Scholar 

  47. Bossuyt X (2009) Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 8:543–548

    Article  PubMed  CAS  Google Scholar 

  48. Rantapaa-Dahlqvist S, deJong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis & Rheumatism 48:2741–2749

    Article  Google Scholar 

  49. Vencovsky J, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430

    Article  PubMed  CAS  Google Scholar 

  50. Feng Y, Ke X, Ma R, Chen Y, Hu G, Liu F (2004) Parallel detection of autoantibodies with microarrays in rheumatoid diseases. Clin Chem 50:416–422

    Article  PubMed  CAS  Google Scholar 

  51. Vallbracht I, Rieber J, Oppermann M, Foerger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084

    Article  PubMed  CAS  Google Scholar 

  52. Hoffman IEA, Peene I, Pottel H, Union A, Hulstaert F, Meheus L, Lebeer K, De Clercq L, Schatteman L, Poriau S, Mielants H, Veys EM, De Keyser F (2005) Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem 51:261–265

    Article  PubMed  CAS  Google Scholar 

  53. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, Sonderstup G, Monach P, Drijfhout JW, van Venrooij WJ, Utz PJ, Genovese MC, Robinson WH (2005) Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 52:2645–2655

    Article  PubMed  CAS  Google Scholar 

  54. Roennelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749

    Article  CAS  Google Scholar 

  55. Cruyssen BV, Cantaert T, Nogueira L, Clavel C, De Rycke L, Dendoven A, Sebag M, Deforce D, Vincent C, Elewaut D, Serre G, De Keyser F (2006) Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arth Res & Ther 8:R122

    Article  Google Scholar 

  56. Maddison P, Huey P (2006) Rheumatic diseases. Serological aids to early diagnosis. Top Rev 8:1–8

    Google Scholar 

  57. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfart J, Frisch M (2006) Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arth Res & Ther 8:R133

    Article  Google Scholar 

  58. Nikolaisen C, Rekvig O, Nossent HC (2007) Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis. Scandinavian J Rheumatol 36:97–100

    Article  CAS  Google Scholar 

  59. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa G, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808

    PubMed  Google Scholar 

  60. Dos Anjos LME, Pereira IA, d’Orsi E, Seaman AP, Burlingame RF, Morato EF (2009) A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 28:153–158

    Article  PubMed  Google Scholar 

  61. Tedesco A, D’Agostino D, Soriente I, Amato P, Piccoli R, Sabatini P (2009) A new strategy for the early diagnosis of rheumatoid arthritis:A combined approach. Autoimmunity Reviews 233–237

  62. Shoenfeld Y, Gershwin ME (2008) Whither autoimmunity: the lessons of Anti-CCP and B cell depletion. Clin Rev Allergy Immunol 34:1–3

    Article  PubMed  Google Scholar 

  63. Wiik AS (2003) Appropriateness of autoantibody testing in clinical medicine. Clin Chim Acta 333:177–180

    Article  PubMed  CAS  Google Scholar 

  64. Villalta D, Tozzoli R, Tonutti E, Bizzaro N (2007) The laboratory approach to the diagnosis of autoimmune diseases: is it time to change? Autoimmunity Reviews 6:359–365

    Article  PubMed  CAS  Google Scholar 

  65. Talapatra A, Rouse R, Hardiman G (2002) Protein microarrays: challenges and promises. Pharmacogenomics 3:1–10

    Article  Google Scholar 

  66. Anderson NL (2005) The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cellu Proteomics 4:1441–1444

    Article  CAS  Google Scholar 

  67. Hueber W, Lee BJ, Genovese M, van Venrooij W, Steinman L, Putz PJ, Robinson WH (2003) Multiplex autoantibody profiling using ‘synovial proteome’ microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis. Arth Res & Ther 5:99

    Article  Google Scholar 

  68. Tjalsma H, Schaeps RM, Swinkels SW (2008) Immunoproteomics: from biomarker discovery to diagnostic applications. Proteomics Clin Appl 2:167–180

    Article  PubMed  CAS  Google Scholar 

  69. Rashtak S, Ettore MW, Homburger HA, Murray JA (2008) Combination testing for antibodies in the diagnosis of celiac disease: comparison of multiplex immunoassay and ELISA methods. Aliment Pharmacol Ther 28:805–813

    Article  PubMed  CAS  Google Scholar 

  70. Hartman M, Schrenk M, Doettinger A, Nagel S, Roeraade J, Joos TO, Templin MF (2008) Expanding assay dynamics: a combined competitive and direct assay system for the quantification of proteins in multiplexed immunoassays. Clin Chem 54:956–963

    Article  Google Scholar 

  71. Plebani M, Pittoni M, Celadin M, Bernadi D, Mion MM (2009) Recent advances in diagnostic technologies for autoimmune diseases. Autoimmunity Reviews 8:238–243

    Article  PubMed  CAS  Google Scholar 

  72. Ellington AA, Kullo IJ, Bailey KR, Klee GG (2009) Measurement and quality control issues in multiplex protein assays: a case study. Clinica Chemistry 55:1092–1099

    Article  CAS  Google Scholar 

  73. Kricka LJ, Master SR (2009) Quality control and protein microarrays. Clin Chem 55:1053–1055

    Article  PubMed  CAS  Google Scholar 

  74. Simon A, Girard-Egrot A, Sauter F, Pudda C, Picollet D’Hahan N, Blum L, Chatelain F, Fuchs A (2007) Formation and stability of a suspended bio-mimetic lipid bilayer on silicon submicrometer-sized pores. J Colloid Interface Science 308:337

    Article  CAS  Google Scholar 

  75. Pierangeli SS, Harris EN (2005) Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 357:17–33

    Article  PubMed  CAS  Google Scholar 

  76. Merkel P, Chang Y, Pierangeli SS, Harris EN, Polisson RP (1999) Comparisons between the standard anticardiolipin antibody test and a new phospholipids test in patients with connective tissue diseases. J Rheumatol 26:591–596

    PubMed  CAS  Google Scholar 

  77. Koike T, Bohgaki M, Amengual O, Atsumi T (2007) Antiphospholipid antibodies: lessons from the bench. J Autoimmunity 28:129–133

    Article  CAS  Google Scholar 

  78. Wong RCW, Favaloro EJ, Adelstein S, Baumgart K, Bird R, Brighton TA, Empson M, Gillis D, Hendle MJ, Laurent R, Mallon D, Pollock W, Smith S, Steele RH, Wilson RJ (2008) Consensus guidelines on ant-beta 2 glycoprotein I testing and reporting. Pathology 40:58–63

    Article  PubMed  CAS  Google Scholar 

  79. Lieby P, Poindron V, Roussi S, Klein C, Knapp A-M, Garaud J-C, Cerutti M, Martin T, Pasquali J-L (2008) Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack. Blood 104:1711–1715

    Article  Google Scholar 

  80. Charles PJ (2004) Multiplex analysis of antinuclear antibodies by flow cytometry using FIDIS. Arthritis Res Ther 6(Suppl 1):8

    Article  Google Scholar 

  81. Gonzalez C, Garcia-Berrocal B, Talavan T, Casas ML, Navajo JA, Gonzalez-Buitrago JM (2005) Clinical evaluation of a microsphere bead-based flow cytometry assay for the simultaneous determination of anti-thyroid peroxidase and anti-thyroglobulin antibodies. Clin Biochem 38:966–972

    Article  PubMed  CAS  Google Scholar 

  82. Tozzoli R, Villalta D, Kodermaz G, Bagnasco M, Tonutti E, Bizarro N (2006) Autoantibody profiling of patients with autoimmune thyroid disease using a new multiplexed immunoassay method. Clin Chem Med 44:837–842

    Article  CAS  Google Scholar 

  83. Martins TB, Burlingame R, von Muehlen CA, Jaskowski TD, Litwin CM, Hill HR (2004) Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 11:1054–1059

    PubMed  CAS  Google Scholar 

  84. Binder SR, Genovese MC, Merrill JT, Morris RI, Metzger AL (2005) Computer-assisted pattern recognition of autoantibody results. Clin Diagn Lab Immunol 12:1353–1357

    PubMed  CAS  Google Scholar 

  85. Grimes DA, Schulz KF (2005) Refining clinical diagnosis with likelihood ratios. Lancet 365:1500–1505

    Article  PubMed  Google Scholar 

  86. Kaul R, Johnson K, Scholz H, Marr G (2009) Performance of the BioPlex™ 2200 autoimmune vasculitis kit. Autoimmunity Reviews 8:224–227

    Article  PubMed  Google Scholar 

  87. Lidar M, Lipschitz N, Langevitz P, Barzilai O, Ram M, Porat-Katz B-S, Pagnoux C, Guilpain P, Sinico RA, Radice A, Bizarro N, Damoiseaux J, Tervaert JWC, Martin J, Guillevin L, Bombardieri S, Shoenfeld Y (2009) Infectious serologies and autoantibodies in Wegener’s granulomatosis and other vasculitides: novel associations disclosed using the Rad BioPlex 2200. Ann N Y Acad Sci 1173:649–657

    Article  PubMed  CAS  Google Scholar 

  88. Hintzen C, Quaiser S, Pap T, Heinrich PC, Hermanns HM (2009) Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arth Rheum 60:2102–2112

    Article  Google Scholar 

  89. Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW (2009) The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arth Rheum 60:2390–2401

    Article  CAS  Google Scholar 

  90. Marta M, Meier UC, Lobell A (2009) Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun Rev 8:506–509

    Article  PubMed  CAS  Google Scholar 

  91. Xiao X, Ma B, Dong B, Zhao P, Tai N, Chen L, Wong FS, Wen L (2009) Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice. J Autoimmun 32:85–93

    Article  PubMed  CAS  Google Scholar 

  92. Enghard P, Humrich JY, Rudolph B, Rosenberger S, Biesen R, Kuhn A, Manz R, Hiepe F, Radbruch A, Burmester GR, Riemekasten G (2009) CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arth Rheum 60:199–206

    Article  CAS  Google Scholar 

  93. Kanazawa Y, Shimada A, Oikawa Y, Okubo Y, Tada A, Imai T, Miyazaki J, Itoh H (2009) Induction of anti-whole GAD65 reactivity in vivo results in disease suppression in type 1 diabetes. J Autoimmun 32:104–109

    Article  PubMed  CAS  Google Scholar 

  94. Yang K, Vega JL, Hadzipasic M, Schatzmann Peron JP, Zhu B, Carrier Y, Masli S, Rizzo LV, Weiner HL (2009) Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis. J Autoimmun 32:94–103

    Article  PubMed  CAS  Google Scholar 

  95. Youinou P, Jamin C (2009) The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 32:206–210

    Article  PubMed  CAS  Google Scholar 

  96. Motrich RD, van Etten E, Depovere J, Riera CM, Rivero VE, Mathieu C (2009) Impact of vitamin D receptor activity on experimental autoimmune prostatitis. J Autoimmun 32:140–148

    Article  PubMed  CAS  Google Scholar 

  97. Adamus G, Karren L (2009) Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy. J Autoimmun 32:133–139

    Article  PubMed  CAS  Google Scholar 

  98. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Goncalves O, Valente J (2009) Behcet’s disease—a contemporary review. J Autoimmun 32:178–188

    Article  PubMed  CAS  Google Scholar 

  99. Chretien P, Chousterman M, Abd Alsamad I, Ozenne V, Rosa I, Barrault C, Lons T, Hagege H (2009) Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis. J Autoimmun 32:201–205

    Article  PubMed  CAS  Google Scholar 

  100. Karosi T, Szekanecz Z, Sziklai I (2009) Otosclerosis: an autoimmune disease? Autoimmun Rev, in press

  101. Czompoly T, Simon D, Czirjak L, Nemeth P (2009) Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 8:692–696

    Article  PubMed  CAS  Google Scholar 

  102. Sa MJ (2009) Acute transverse myelitis: a practical reappraisal. Autoimmun Rev, in press

  103. Invernizzi P, Pasini S, Selmi C, Gershwin ME, Podda M (2009) Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun 33:12–16

    Article  PubMed  CAS  Google Scholar 

  104. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz de Rabago E, Sanchez-Ramon S, Rodriguez-Mahou M, Paravisini A, Monteagudo I, Gonzalez CM, Garcia-Castro M, Casas MD, Carreno L (2009) Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arth Rheum 61:419–424

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SQI Diagnostics, 36 Meteor Drive, Toronto, ON, Canada, M9W 1A4

    Peter Lea, Sasi Mudumba, Anthony Kahama, Shi-Fa Ding & Jennifer Hansen

  2. Rebecca MacDonald Centre for Arthritis & Autoimmune Diseases, Mount Sinai Hospital, 60 Murray St., Toronto, ON, M5T 3L9, Canada

    Edward Keystone & Deborah Weber

  3. Mount Sinai Hospital, Pathology and Laboratory Medicine, 600 University Ave, Toronto, ON, M5G 1X5, Canada

    Azar A. Azad

  4. Clinical Pathology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Sihe Wang

Authors
  1. Peter Lea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward Keystone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sasi Mudumba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anthony Kahama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shi-Fa Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jennifer Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Azar A. Azad
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sihe Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Deborah Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Keystone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lea, P., Keystone, E., Mudumba, S. et al. Advantages of Multiplex Proteomics in Clinical Immunology. Clinic Rev Allerg Immunol 41, 20–35 (2011). https://doi.org/10.1007/s12016-009-8189-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-009-8189-z

Keywords

Search

Navigation